ArticleThe Journal of experimental medicine2005
Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 109 citations in OpenAlex.
- Outcomes of Percutaneous Coronary Intervention in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2026Article
- The complement system in lipid-mediated pathologies.Frontiers in immunology · 2024Review
- Effect of diabetes on efferocytosis process.Molecular biology reports · 2022Review
- Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort.Cardiovascular diabetology · 2022Article
- Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.BMC nephrology · 2022Article
- Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction.Clinical and experimental immunology · 2019Article
- Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study.Arthritis research & therapy · 2019Observational
- The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System.Frontiers in immunology · 2019Review
- High rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele.BMC cardiovascular disorders · 2017Article
- Lectin Pathway of Complement Activation Is Associated with Vulnerability of Atherosclerotic Plaques.Frontiers in immunology · 2017Article
- Mannose-binding lectin 2 (Mbl2) gene polymorphisms are related to protein plasma levels, but not to heart disease and infection by Chlamydia.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Article
- Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients.Journal of translational medicine · 2016Article
- Mannose-Binding Lectin Levels and Carotid Intima-Media Thickness in Type 2 Diabetic Patients.Journal of diabetes research · 2016Article
- Mannan-binding lectin in cardiovascular disease.BioMed research international · 2014Review
- The lectin pathway of complement and rheumatic heart disease.Frontiers in pediatrics · 2014Review
- MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans.International journal of cardiology · 2013Article
- Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study.Cardiovascular diabetology · 2011Article
- Mannan Binding Lectin (MBL) genotypes coding for high MBL serum levels are associated with rheumatoid factor negative rheumatoid arthritis in never smokers.Arthritis research & therapy · 2011Article
- Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.Diabetes care · 2010Article
- Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation can predispose to myocardial infarction (MI), and mannan binding lectin (MBL) promotes phagocytic clearance of inflammatory agents, but the predictive value of MBL levels for MI is not known. MBL was analyzed in subgroups of the population-based Reykjavik study, a cohort of 19,381 participants recruited from 1967. MBL levels were very stable over time (self correlation: 0.86). In a cross-sectional group from the original cohort (n = 987), high MBL (>1,000 microg/L) was associated with a greatly lowered odds ratio for MI (0.64, P < 0.001). To verify this finding, a nested case control sample (n = 1,309) was randomly selected from the cohort. High MBL at recruitment was also associated with decreased MI risk in this follow-up group, but to a lesser extent and not significant for the whole group, smokers, or hypertensive individuals. However, high MBL was as in the cross-sectional group, associated with greatly decreased MI risk in diabetic (P = 0.02) or hypercholesterolemic individuals (P = 0.004). This also applied to raised erythrocyte sedimentation rate (P = 0.007). Diabetic patients with high MBL did not have a higher MI risk than nondiabetic individuals. Our findings indicate that high MBL may predict decreased likelihood of MI, particularly in diabetics, and are consistent with the possibility that MBL may promote clearance of atherogenic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.